WOOJUNG BIO, Inc.

KOSDAQ:A215380 Stock Report

Market Cap: ₩26.2b

WOOJUNG BIO Past Earnings Performance

Past criteria checks 3/6

WOOJUNG BIO has been growing earnings at an average annual rate of 8.4%, while the Life Sciences industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 5.4% per year. WOOJUNG BIO's return on equity is 10.8%, and it has net margins of 5.9%.

Key information

8.4%

Earnings growth rate

8.3%

EPS growth rate

Life Sciences Industry Growth53.7%
Revenue growth rate5.4%
Return on equity10.8%
Net Margin5.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

WOOJUNG BIO, Inc.'s (KOSDAQ:215380) 27% Dip In Price Shows Sentiment Is Matching Revenues

Dec 09
WOOJUNG BIO, Inc.'s (KOSDAQ:215380) 27% Dip In Price Shows Sentiment Is Matching Revenues

Why Investors Shouldn't Be Surprised By WOOJUNG BIO, Inc.'s (KOSDAQ:215380) 30% Share Price Plunge

Oct 14
Why Investors Shouldn't Be Surprised By WOOJUNG BIO, Inc.'s (KOSDAQ:215380) 30% Share Price Plunge

WOOJUNG BIO, Inc.'s (KOSDAQ:215380) Shares Bounce 43% But Its Business Still Trails The Industry

Aug 16
WOOJUNG BIO, Inc.'s (KOSDAQ:215380) Shares Bounce 43% But Its Business Still Trails The Industry

Revenues Working Against WOOJUNG BIO, Inc.'s (KOSDAQ:215380) Share Price Following 26% Dive

Jun 14
Revenues Working Against WOOJUNG BIO, Inc.'s (KOSDAQ:215380) Share Price Following 26% Dive

Is WOOJUNG BIO (KOSDAQ:215380) Weighed On By Its Debt Load?

May 23
Is WOOJUNG BIO (KOSDAQ:215380) Weighed On By Its Debt Load?

Revenue & Expenses Breakdown

How WOOJUNG BIO makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A215380 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2449,1362,8927,314417
30 Jun 2444,7531,1817,893340
31 Mar 2440,667-2,8228,055330
31 Dec 2338,616-5,0547,803294
30 Sep 2331,366-4,9278,025299
30 Jun 2336,457-3,0377,515387
31 Mar 2341,790-4,8047,183490
31 Dec 2246,918-1,8806,692614
30 Sep 2243,584-6,5827,067711
30 Jun 2243,180-5,1347,275689
31 Mar 2235,409-3,1977,560633
31 Dec 2131,238-1,9267,742538
30 Sep 2134,042-3,5158,332247
30 Jun 2129,760-12,4327,807663
31 Mar 2131,702-11,6828,763542
31 Dec 2037,344-10,8799,203621
30 Sep 2036,141-8,7728,229982
30 Jun 2037,3432,5788,755731
31 Mar 2038,9807707,5861,018
31 Dec 1932,2902806,6151,136
30 Sep 1932,016-6518,3421,214
30 Jun 1930,400-3,6488,2641,272
31 Mar 1926,507-2,4518,1691,314
31 Dec 1823,758-4,6178,2431,390
30 Sep 1824,213-4,0256,8851,435
30 Jun 1825,433-3,7826,6361,445
31 Mar 1828,077-8,9476,5641,506
31 Dec 1728,932-6,9216,2381,436
30 Sep 1726,053-5,7644,4211,203
30 Jun 1735,254-4,9097,0272,060
31 Mar 1723,9231,5044,3051,469
31 Dec 1621,4791,1254,3561,345
30 Sep 1626,7072,9525,2101,158
30 Jun 1611,4511,8161,255-69
31 Mar 1618,7511,7073,801173
31 Dec 1518,6951,3544,160104
31 Dec 1414,8608804,046482
31 Dec 1315,5871,3482,346255

Quality Earnings: A215380 has high quality earnings.

Growing Profit Margin: A215380 became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A215380 has become profitable over the past 5 years, growing earnings by 8.4% per year.

Accelerating Growth: A215380 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: A215380 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (39.6%).

Return on Equity

High ROE: A215380's Return on Equity (10.8%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 08:45
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

WOOJUNG BIO, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jae Hoon ShinHanwha Investment & Securities Co., Ltd.